Treatment Options in Urological Cancer

Cancer forms a large part of urological practice. Prostate cancer is the most significant and is the second most common cause of male cancer deaths with some 300,000 cases in the USA annually. Cancer of the bladder is also common. While treatment has been primarily surgical, recent years have seen an explosion of new drug therapies for urological cancers.All urologists, whether in training or in practice, need an up-to-date survey of the literature and key findings in this important and controversial field.This book takes each organ in turn (prostate, kidney, bladder, testis and penis) and tackles the controversies head-on by inviting chapters on various (often rival) treatments for each disease. Each section is then concluded by a commentary from the editor which draws together the various strands, outlines the principal areas of consensus and disagreement.Jonathan Waxman is an oncologist who specialises in urological tumours and has developed new treatments for prostate, bladder and kidney cancer and for terminal care, which are now part of standard practice. He founded the Prostate Cancer Charity and helped establish an all-party parliamentary group to improve cancer treatment and research throughout the UK.

Jonathan Waxman is a Professor of Oncology at the Hammersmith Hospital, Imperial College School of Medicine, London. He is a highly experienced clinician who has developed new treatments for cancer, which are now part of standard practice. He is the author of 250 research papers and chapters, and eleven books on cancer.